Browse the evidence

Semaglutide use is associated with oral adverse effects, specifically xerostomia (dry mouth) and hyposalivation, likely due to prolonged GLP-1 receptor activation disrupting salivary gland signaling.

If you are taking semaglutide and experience persistent dry mouth, do not assume it is solely due to dehydration. The drug's prolonged action on salivary glands can reduce saliva production directly. Consult your provider for preventive oral care strategies to manage this side effect.

Patients often learn about semaglutide and tirzepatide from social media and support groups rather than healthcare providers, who act as 'gatekeepers' rather than initial educators.

If you are interested in semaglutide or tirzepatide, do not assume your doctor will bring it up. You likely learned about it from social media or friends. Bring this information to your appointment, as providers may not be the initial source of this information but are necessary for safe access.

Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.

If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.

Older adults may experience higher rates of adverse events and treatment intolerance with AOMs compared to younger adults, particularly gastrointestinal issues and risks related to dehydration and falls.

Be aware that older adults may experience more side effects from weight loss medications, such as nausea or dizziness. This can lead to dehydration or falls. It is important to work closely with a doctor to manage these side effects.

In visceral adipose tissue (VAT) of individuals with obesity and prediabetes, GLP-1, GIP, and glucagon distinctively modulate metabolic profiles, with GLP-1 shifting metabolism toward anaerobic glycolysis (increased lactate/alanine) and the other two hormones promoting oxidative phosphorylation (increased pyruvate consumption), suggesting an overall improvement in mitochondrial function.

For individuals with obesity and prediabetes, gut hormones like GLP-1, GIP, and glucagon do not act uniformly on fat tissue. GLP-1 appears to shift VAT metabolism toward anaerobic pathways (increasing lactate and alanine), while GIP and glucagon may support mitochondrial function by increasing pyruvate consumption. This suggests that the metabolic health status (specifically prediabetes) significantly alters how fat tissue responds to these hormones, potentially explaining varied clinical outcomes in weight loss and glycemic control therapies.

Tirzepatide use is strongly associated with a high frequency of dosing errors, particularly incorrect dose administration, which increases significantly over time and correlates with strong statistical safety signals.

If you are using tirzepatide, be aware that dosing errors are the most common side effect reported. The once-weekly schedule and mandatory dose increases can be confusing. Use a calendar or app to track your injections and strictly follow the titration steps to avoid mistakes.

Tirzepatide is associated with injection-site reactions, particularly pain, which are consistent with the class of GLP-1/GIP agonists and are typically mild and transient.

Injection site pain is a common side effect of tirzepatide. It is usually mild and goes away. Proper injection technique and counseling can help reduce this discomfort and help you stick with your treatment.

Gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, are frequent side effects of tirzepatide, particularly during initiation and titration phases.

GI side effects like nausea and diarrhea are common with tirzepatide, especially when starting or increasing the dose. Talk to your doctor about managing these symptoms with diet changes or medication to help you stay on treatment.

Other protein supplements (soy, casein, pea, rice, etc.) do not show statistically significant differences in muscle strength or fat-free mass gains compared to placebo in healthy adults undergoing resistance training.

If you are using other protein supplements like soy, casein, or pea protein, they may not provide significant additional benefits for muscle strength or mass gains compared to a placebo. Focus on collagen or whey if you want to maximize your results.

Targeting endogenous enteroendocrine cell (EEC) secretion to mimic postprandial hypersecretion of GLP-1 and other GI hormones offers a potential treatment for obesity and type 2 diabetes that avoids the side effects of exogenous GLP-1-based drugs.

Current research suggests that stimulating your gut to release its own GLP-1 (perhaps through specific nutrients or future drugs) might help with weight loss and blood sugar control without the nausea or nutrient malabsorption seen with current GLP-1 injections. This is still experimental.

GLP-1 receptor agonist pharmacotherapy in older adults causes significant loss of lean skeletal muscle mass (approx. 26-40% of total weight lost), which independently predicts adverse outcomes including mortality, functional decline, and frailty.

If you are an older adult using GLP-1 medications, do not focus solely on the number on the scale. The medication causes you to lose muscle along with fat, which can lead to frailty and higher mortality. You must actively counteract this by combining your medication with resistance exercise and adequate protein intake to preserve your muscle mass.

Semaglutide induces adipose tissue remodeling in Type 2 Diabetes by promoting mitochondrial biogenesis, inducing beige adipocyte programming, and reducing visceral adiposity, leading to improved systemic insulin sensitivity and reduced ectopic fat deposition.

For individuals with T2DM or obesity, semaglutide offers benefits that go beyond simple weight loss. It actively remodels fat tissue, particularly visceral fat, making it more metabolically active and less inflammatory. This leads to improved insulin sensitivity and reduced liver fat, which are critical for long-term metabolic health. The medication is taken once weekly, with doses tailored to whether the goal is managing diabetes (up to 1.0 mg) or weight loss (up to 2.4 mg).

Tirzepatide promotes sustained improvements in skeletal muscle mitochondrial respiration and ATP production under lipotoxic conditions, whereas semaglutide and cagrilintide cause transient suppression that resolves over time.

If you are using incretin-based therapies like tirzepatide, this in vitro evidence suggests your muscle cells may become more efficient at producing energy over time, even under metabolic stress. While other drugs in this class (semaglutide, cagrilintide) show temporary dips in mitochondrial function, tirzepatide appears to enhance it. This supports the importance of resistance training to leverage these cellular adaptations for maintaining muscle quality.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.

If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.

Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.

While postmarketing reports of neoplasms are higher for GLP-1 RAs, they are still rare. The benefits of weight loss and mortality reduction likely outweigh this small risk for most patients.

Primary care physicians' proactivity in prescribing pharmaceutical weight loss treatments is significantly correlated with their belief in the efficacy of those treatments and their specific knowledge of the agents, whereas lack of knowledge is the predominant barrier for less proactive physicians.

For primary care physicians, the key to expanding obesity treatment options is not just access to drugs, but targeted education and clear guidelines. Physicians who feel knowledgeable and confident are significantly more likely to prescribe effective pharmaceutical interventions like liraglutide. Updating guidelines and providing continuous education can directly increase proactive prescribing.

Semaglutide is associated with a higher incidence of symptomatic gastrointestinal adverse events compared to dulaglutide in the context of emergency exposures.

If you experience severe nausea or vomiting on semaglutide, talk to your doctor. They might switch you to a different GLP-1 medication, like dulaglutide, which may have fewer gastrointestinal side effects for you.

Obesity involves molecular mechanisms, including metabolic memory and epigenetic modifications, that actively hinder weight loss and promote weight regain.

If you are struggling to lose weight despite diet and exercise, recognize that your body has biological defenses (like metabolic memory and hormonal shifts) that actively work to restore previous weight. This is not a failure of willpower but a known physiological response. Addressing these barriers may require a multidisciplinary approach, potentially including medical interventions, rather than just stricter dieting.

Epigenetic changes, such as DNA methylation and histone modifications, can persist after weight loss and contribute to weight regain.

Weight loss can trigger long-lasting epigenetic changes that make your body more prone to regaining weight. This means maintaining weight loss might require ongoing effort and potentially medical support, as your body's 'default setting' may have shifted.

Adipose tissue dysfunction, characterized by chronic low-grade inflammation and insulin resistance, creates a self-perpetuating cycle that promotes obesity.

Excess fat, especially around the abdomen, is not just inert storage but an active organ that releases inflammatory signals. These signals can cause insulin resistance and further fat storage, creating a cycle that is hard to break without addressing the underlying inflammation.

Rapid and significant weight loss induced by Tirzepatide leads to aesthetic changes, including facial volume loss ('Ozempic face'), skin laxity, and altered collagen structure, which are secondary to fat loss rather than direct drug toxicity.

Significant weight loss can cause your face to look older or saggy due to loss of facial fat. This is a side effect of the weight loss, not the drug itself. Eating enough protein and vitamins (like D and B12) during treatment may help maintain skin health.

GLP-1 receptor agonists may interact with oral systemic cancer therapies by delaying gastric emptying, potentially altering absorption kinetics (time to peak concentration) without necessarily changing total drug exposure.

If you take oral cancer pills along with GLP-1 drugs (like Ozempic), tell your doctor. The GLP-1 drug might slow down how fast your cancer pills are absorbed. This doesn't always mean the treatment won't work, but your doctor needs to know to monitor you closely.

GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.

In Brazil, access to GLP-1 drugs like semaglutide is currently determined by your state's economic wealth rather than your obesity rates. Public health policy has excluded these drugs from free coverage, creating a market where only those with higher income can afford them, regardless of medical need.

Semaglutide is the predominant GLP-1 RA in Brazil, driving the majority of sales growth and adverse event reports, with significant off-label use for weight loss.

Semaglutide is the most widely used GLP-1 drug in Brazil. A significant portion of its use is off-label for weight loss, which generates specific adverse event reports and requires careful monitoring.